Lilly, Novo to lower obesity drug prices in Trump deal

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs such as Zepbound and Wegovy in exchange for tariff relief and wider Medicare access.  The deals, announced Thursday at a White House event with US President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.The companies’ medicines will receive a three-year grace period ...